HOME
- Details
- Written by: web web
- Category: Home
- Hits: 644
Lead Program
Gain’s lead drug candidate GT-02287 is a best-in-class small molecule, for the treatment of GBA-Parkinson’s disease and other neurodegenerative diseases. GT-02287 is currently being evaluated in a Phase I clinical study.
Lead Program >>
- Details
- Written by: web web
- Category: Home
- Hits: 744
OUR DRUG DISCOVERY PLATFORM MAGELLAN™
By leveraging AI-supported 3D structural biology and supercomputer-powered proprietary physics-based models, Gain’s Magellan™ platform is able to identify novel allosteric binding sites on disease-implicated proteins and exploit their untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies.
Our Platform >>
- Details
- Written by: web web
- Category: Home
- Hits: 761
ALLOSTERIC PROTEIN REGULATION
Our next generation allosteric small molecule therapeutics can modulate a protein to restore or disrupt function, not just through inhibition or activation, but also through stabilization, destabilization and degradation, based on disease pathology.
Our Science >>
- Details
- Written by: web web
- Category: Home
- Hits: 1127
PRESS RELEASES
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase ...
BETHESDA, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the...